Anti-VEGF treatment continues for years in most neovascular AMD patients

Ranibizumab treatment was discontinued in 21% of neovascular age-related macular degeneration patients because of complete inactivation of choroidal neovascularization, a long-term study found.Fifteen percent of patients failed to respond to treatment, and 64% of patients needed continuous treatment for as long as 4 years.

Full Story →